Skip to main content
. 2020 Apr 13;25(8):1778. doi: 10.3390/molecules25081778

Table 1.

Drugs and inhibitors of NEK family members.

Drug Name Chemical Formula NEK Targets Action/Effects Stage of Development Selectivity References
Fostamatinib C23H26FN6O9P NEK1
NEK3
NEK4
NEK5
NEK9
NEK11
Inhibits signal transduction by Fcγ receptors involved in the antibody-mediated destruction of platelets. NEKs 1,2,3,4 5,9,11 are included in the list of targets Approved for the treatment of chronic immune thrombocytopenia (ITP). Under investigation for other diseases The active metabolite of fostamatinib, named R406, presents a lack of selectivity among several kinases [203]
5-[(Z)-(5-Chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene) methyl]-N,2,4-trimethyl-1H-pyrrole-3-carboxamide C17H16ClN3O2 NEK2 Interacts with NEK2 Experimental No off-targets have been described [204]
NCI code 51,525 and 58991 - NEK2 Inhibits NEK2 Experimental No off-targets have been described [205]
MBM-17 and MBM-55 C28H29N6 and
C28H28N6O2F
respectively
NEK2 Inhibits NEK2 and has antiproliferative/antitumor properties Experimental It has low nanomolar activity and a great selectivity for NEK2 [206]
di-demethylchlorpromazine and 2-[5-fluoro-1H-indol-3-yl] propan-1-amine C15-H15-Cl-N2-S.Cl-H and C11H14ClFN2 respectively NEK2 Inhibits NEK2 Pre-experimental (in silico) No off-targets have been described [207]
(5Z)-2-hydroxy-4-methyl-6-oxo-5-[(5-phenylfuran-2-yl)methylidene]-5,6-dihydropyridine-3-carbonitrile) or compound 8 C22H24F3N8O2 NEK6
NEK1
Inhibits NEK6. Displays anti-proliferative effects on several cancer cell lines with low IC50 values. Induces cell cycle arrest in the G2/M phases and has a synergistic effect with cisplatin and paclitaxel in ovarian cancer. It can inhibit NEK1. Experimental Inhibits NEK6 and NEK1. No off-targets have been described [208]
Metformin C4H11N5 NEK7 Metformin inhibits NEK7 expression in an experimental diabetic periodontitis model Approved for type II diabetes Activates AMPK, inhibits electron transfer flavoprotein-ubiquinone oxidoreductase (ETFDH), and glycerol-3-phosphate dehydrogenase [NAD(+)] (GPD1) [175,209,210,211]
Ethyl 1-(2-hydroxypentyl) 5-(3-(3-(trifluoromethyl) phenyl)ureido)-1H-pyrazole-4-carboxylate or GeGe3 - NEK10 Screening for GeGe3-targeted kinases revealed NEK10 as candidate targets, such as Aurora B. Inhibits physiological and tumor angiogenesis. Experimental Strongly inhibits aurora B, aurora C, NEK 10, polo like kinases 2 and 3 (PLK2/PLK3), dystrophia myotonica protein kinase 1 (DMPK), and calcium/calmodulin-dependent protein kinase type 1 (CaMK1) [212]
Dabrafenib C23H20F3N5O2S2 NEK11 Reduces the proliferation and regression of tumors in xenograft models. Approved for the treatment of metastatic melanoma with BRAF V600E mutations Inhibits serine/threonine-protein kinase B-raf (BRAF1), proto-oncogene c-RAF (RAF), serine/threonine-protein kinase SIK1 (SIK-1), NEK11, and LIM domain kinase 1 (LIMK-1) [213,214]